Nautilus Biotechnology (NAUT) Free Cash Flow Growth (1y) (2021 - 2026)

Nautilus Biotechnology (NAUT) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 7.12%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 1,092.51%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 66.37%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 3.98%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Nautilus Biotechnology 212.11 Mn 116.24 Mn - 3.86%

Historic Data

Download Data
DateValue
Mar 31, 2026 3.86%
Dec 31, 2025 13.35%
Sep 30, 2025 17.15%
Jun 30, 2025 13.92%
Mar 31, 2025 16.30%
Dec 31, 2024 -1.75%
Sep 30, 2024 -9.59%
Jun 30, 2024 -13.97%
Mar 31, 2024 -27.97%
Dec 31, 2023 -34.95%
Sep 30, 2023 -19.79%
Jun 30, 2023 1.18%
Mar 31, 2023 -3.12%
Dec 31, 2022 7.81%
Sep 30, 2022 27.13%
Jun 30, 2022 -60.72%
Mar 31, 2022 -90.29%
Dec 31, 2021 -1,247.87%
Sep 30, 2021 -1,832.33%